Edition:
United States

Thermon Group Holdings Inc (THR)

THR on New York Consolidated

17.62USD
19 Sep 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$17.62
Open
$17.76
Day's High
$17.80
Day's Low
$17.59
Volume
84,694
Avg. Vol
142,858
52-wk High
$21.48
52-wk Low
$15.74

Latest Key Developments (Source: Significant Developments)

Thermon Group Holdings reports first quarter fiscal 2018 results
Wednesday, 2 Aug 2017 08:00am EDT 

Aug 2 (Reuters) - Thermon Group Holdings Inc :Thermon reports first quarter fiscal 2018 results.Q1 gaap earnings per share $0.01.Q1 revenue $51.7 million versus I/B/E/S view $58.3 million.Q1 earnings per share view $0.04 -- Thomson Reuters I/B/E/S.Thermon Group Holdings Inc says revising full year fiscal 2018 revenue guidance to a low to mid single-digit decline as compared to fiscal 2017.Thermon Group Holdings Inc qtrly orders of $55.1 million, a 29% decrease.Thermon Group Holdings Inc qtrl- end backlog of $110.2 million versus. $95.4 million, growth of 16%.  Full Article

Thermon Group files for mixed shelf of up to $250 mln
Tuesday, 20 Jun 2017 05:06pm EDT 

June 20 (Reuters) - Thermon Group Holdings Inc :Thermon Group Holdings Inc files for mixed shelf of up to $250 million - SEC filing.  Full Article

Thermon reports Q4 adjusted earnings per share $0.10
Wednesday, 24 May 2017 08:00am EDT 

May 24 (Reuters) - Thermon Group Holdings Inc ::Thermon reports fiscal 2017 results.Q4 revenue $67.6 million versus I/B/E/S view $66.2 million.Q4 adjusted earnings per share $0.10.Q4 earnings per share view $0.13 -- Thomson Reuters I/B/E/S.Expects fiscal 2018 revenue to be flat to slightly down from fiscal 2017 levels.Qtrly backlog of $107.0 million, an increase of 32pct.Q4 2017 orders were $69.4 million versus $72.6 million in Q4 2016.Expects fiscal 2018 revenue to be flat to slightly down from fiscal 2017 levels.  Full Article

Thrombogenics achieves important milestone in development of THR-149, novel plasma kallikrein inhibitor for diabetic macular edema
Thursday, 20 Apr 2017 01:49am EDT 

April 20 (Reuters) - Thrombogenics NV ::Achieves important milestone in the development of THR-149, a novel plasma kallikrein inhibitor for diabetic macular edema.Has an exclusive license to undertake pre-clinical and clinical development.Bicycle Therapeutics receives development milestone payments and royalties on sales of products resulting from collaboration.  Full Article

Thermon reports Q3 adjusted earnings $0.16/shr
Wednesday, 8 Feb 2017 08:00am EST 

Thermon Group Holdings Inc : Thermon reports third quarter fiscal 2017 results . Q3 adjusted earnings per share $0.16 . Q3 GAAP earnings per share $0.16 . Q3 earnings per share view $0.17 -- Thomson Reuters I/B/E/S . Q3 revenue $64.3 million versus I/B/E/S view $70 million . Thermon Group Holdings Inc - qtrly backlog of $105.0 million, an increase of 30 percent . Sees FY 2017 revenue down about 7 percent . FY 2017 revenue view $271.0 million -- Thomson Reuters I/B/E/S . Thermon Group Holdings Inc- Continues to experience project construction delays by customers and deferral of capital and maintenance spending for Q4 .Thermon Group Holdings - Revenue guidance reflects anticipated revenue decline of approximately 7 percent for fiscal 2017 as compared to fiscal 2016.  Full Article

Thermon Group holdings qtrly backlog of $95.4 mln vs $76.4 mln at Q1 2016
Wednesday, 3 Aug 2016 08:00am EDT 

Thermon Group Holdings Inc : Maintaining its revenue guidance of flat to low single-digit growth in fiscal 2017 . Q1 2017 orders were $77.5 million versus $63.9 million in q1 2016 . Thermon group holdings inc qtrly backlog of $95.4 million compared to $76.4 million at q1 2016 . Thermon group holdings inc says expects second half of year to be stronger than first half based on timing of projects currently in backlog . Thermon group holdings inc says anticipates that gross margin pressure experienced during q1 will continue in near term Further company coverage: [THR.N] (Bengaluru Newsroom: +1-646-223-8780).  Full Article

Thermon group holdings Q1 adjusted earnings per share $0.08
Wednesday, 3 Aug 2016 08:00am EDT 

Thermon Group Holdings Inc : Q1 gaap earnings per share $0.08 . Q1 earnings per share view $0.15 -- Thomson Reuters I/B/E/S . Thermon reports first quarter fiscal 2017 results . Q1 revenue $63.4 million versus i/b/e/s view $64.1 million . Q1 adjusted earnings per share $0.08 Further company coverage: [THR.N] (Bengaluru Newsroom: +1-646-223-8780).  Full Article

Thermon Group reports Q4 adjusted earnings per share $0.20
Wednesday, 25 May 2016 08:00am EDT 

Thermon Group Holdings Inc : Thermon reports fiscal 2016 results . Q4 revenue $72.3 million versus I/B/E/S view $65.2 million . Q4 adjusted earnings per share $0.20 . Q4 earnings per share view $0.19 -- Thomson Reuters I/B/E/S . Quarter-End backlog of $81.2 million compared to $75.7 million at end of Q4 2015 . Q4 2016 orders were $72.6 million, a 39 pct increase over Q4 2015 . Thermon Group Holdings Inc qtrly diluted GAAP EPS of $0.10 .Forecasting flat to low single digit top line revenue growth in fiscal 2017 as compared to fiscal 2016.  Full Article

Thermon Group Holdings Inc updates FY 2016 revenue guidance
Wednesday, 3 Feb 2016 07:58am EST 

Thermon Group Holdings Inc:Says the company updating its FY 2016 guidance to reflect a top line revenue percentage decline of 10% to 12% as compared to Fy 2015, which includes revenue contributions from recent acquisitions.  Full Article

Thermon Group Holdings, Inc announces CEO succession
Tuesday, 8 Dec 2015 08:58am EST 

Thermon Group Holdings, Inc:Announces CEO succession.Rodney bingham, president and CEO, will retire upon the expiration of his current employment agreement on March 31, 2016.Says bruce thames, current executive vice president and chief operating officer, will succeed bingham.Prior to joining Thermon, thames was senior vice president and chief operating officer of td williamson in Tulsa, Oklahoma.  Full Article